Literature DB >> 24715043

Risk estimator for adrenal tumor functionality.

Claire Sadler1, Melanie Goldfarb.   

Abstract

BACKGROUND: Adrenal lesions are a common imaging finding with a prevalence approaching 10%. Although guidelines recommend dedicated laboratory tests to rule out tumor functionality, many patients never undergo this workup. This study investigates the use of demographic and clinical variables to create an easy scoring system for predicting adrenal tumor functionality (functional adrenal tumors, or FATs).
METHODS: Altogether, 2,807 patients in the NSQIP 2005-2010 database underwent adrenalectomy as their principal operation and had a postoperative diagnosis consistent with an adrenal lesion/disorder. Patients were divided into two groups based on a postoperative diagnosis consistent with tumor functionality. Univariate and multivariate logistic regression analyses were performed to identify specific predictors of FATs and for Cushing's, Conn's, or pheochromocytoma.
RESULTS: Overall, 13.2% (n = 402) of adrenalectomies performed were for FATs. Patients with a FAT were younger (age <40, p < 0.01), overweight (BMI > 30 kg/m(2), p < 0.01), hypertensive (p < 0.001). They also had elevated white blood cells (WBC > 11, p < 0.001), serum creatinine (Cr > 1.25 mg/dl, p < 0.001), and sodium (Na > 143 mmol/L, p < 0.001). On multivariate regression, patients with these characteristics were 20.53 times (CI 15.79-25.27) more likely to have a FAT (model c-statistic 0.634, CI 0.605-0.663; Hosmer-Lemeshow test (H-L), p = 0.035). Patients who were younger (p < 0.001), female (p < 0.001), diabetic (p = 0.07), overweight (p = 0.027), with elevated WBCs (p < 0.001) and lower Cr (p < 0.001) were 63.62 times (CI 58.03-69.21) more likely to have Cushing's (model c-statistic 0.685, CI 0.648-0.722; H-L p = 0.954).
CONCLUSIONS: After external validation, this risk estimator might be used to quantify the probability of tumor functionality in patients with incidental adrenal masses. Although predictive power may be limited, it helps identify patients at high risk for FATs that need more urgent referral to a specialist.

Entities:  

Mesh:

Year:  2014        PMID: 24715043     DOI: 10.1007/s00268-014-2524-0

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  29 in total

1.  Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features.

Authors:  R Rossi; L Tauchmanova; A Luciano; M Di Martino; C Battista; L Del Viscovo; V Nuzzo; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2000-04       Impact factor: 5.958

Review 2.  Adrenal incidentalomas and subclinical Cushing's syndrome: is there evidence for glucocorticoid-induced osteoporosis?

Authors:  A Angeli; G Osella; G Reimondo; M Terzolo
Journal:  Front Horm Res       Date:  2002       Impact factor: 2.606

3.  Development of overt Cushing's syndrome in patients with adrenal incidentaloma.

Authors:  Luisa Barzon; Francesco Fallo; Nicoletta Sonino; Marco Boscaro
Journal:  Eur J Endocrinol       Date:  2002-01       Impact factor: 6.664

4.  Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk.

Authors:  Libuse Tauchmanovà; Riccardo Rossi; Bernadette Biondi; Melania Pulcrano; Vincenzo Nuzzo; Emiliano-Antonio Palmieri; Serafino Fazio; Gaetano Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2002-11       Impact factor: 5.958

5.  Cohort study of patients with adrenal lesions discovered incidentally.

Authors:  A Muth; L Hammarstedt; M Hellström; H Á Sigurjónsdóttir; E Almqvist; B Wängberg
Journal:  Br J Surg       Date:  2011-05-27       Impact factor: 6.939

Review 6.  Endocrine incidentalomas--challenges imposed by incidentally discovered lesions.

Authors:  Dimitra A Vassiliadi; Stylianos Tsagarakis
Journal:  Nat Rev Endocrinol       Date:  2011-06-28       Impact factor: 43.330

Review 7.  Incidentalomas. A disease of modern technology.

Authors:  R M Chidiac; D C Aron
Journal:  Endocrinol Metab Clin North Am       Date:  1997-03       Impact factor: 4.741

Review 8.  NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma").

Authors: 
Journal:  NIH Consens State Sci Statements       Date:  2002 Feb 4-6

9.  Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink?

Authors:  T J Cawood; P J Hunt; D O'Shea; D Cole; S Soule
Journal:  Eur J Endocrinol       Date:  2009-05-13       Impact factor: 6.664

10.  Risk factors associated with a low glomerular filtration rate in primary aldosteronism.

Authors:  Martin Reincke; Lars Christian Rump; Marcus Quinkler; Stephanie Hahner; Sven Diederich; Reinhard Lorenz; Jochen Seufert; Caroline Schirpenbach; Felix Beuschlein; Martin Bidlingmaier; Christa Meisinger; Rolf Holle; Stephan Endres
Journal:  J Clin Endocrinol Metab       Date:  2008-12-30       Impact factor: 5.958

View more
  1 in total

1.  The prevalence and characteristics of non-functioning and autonomous cortisol secreting adrenal incidentaloma after patients' stratification by body mass index and age.

Authors:  Ana Podbregar; Andrej Janez; Katja Goricar; Mojca Jensterle
Journal:  BMC Endocr Disord       Date:  2020-07-31       Impact factor: 2.763

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.